-
Something wrong with this record ?
Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment
J. Gruchot, I. Lewen, M. Dietrich, L. Reiche, M. Sindi, C. Hecker, F. Herrero, B. Charvet, U. Weber-Stadlbauer, HP. Hartung, P. Albrecht, H. Perron, U. Meyer, P. Küry
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 1915 to 6 months ago
Freely Accessible Science Journals
from 1915 to 6 months ago
PubMed Central
from 1915 to 6 months ago
Europe PubMed Central
from 1915 to 6 months ago
Open Access Digital Library
from 1915-01-01
Open Access Digital Library
from 1915-01-15
- MeSH
- Endogenous Retroviruses * genetics MeSH
- Animals, Genetically Modified MeSH
- Humans MeSH
- Myelin Sheath MeSH
- Mice MeSH
- Neuroglia MeSH
- Multiple Sclerosis * genetics MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The human endogenous retrovirus type W (HERV-W) has been identified and repeatedly confirmed as human-specific pathogenic entity affecting many cell types in multiple sclerosis (MS). Our recent contributions revealed the encoded envelope (ENV) protein to disturb myelin repair by interfering with oligodendroglial precursor differentiation and by polarizing microglial cells toward an axon-damage phenotype. Indirect proof of ENV's antiregenerative and degenerative activities has been gathered recently in clinical trials using a neutralizing anti-ENV therapeutic antibody. Yet direct proof of its mode of action can only be presented here based on transgenic ENV expression in mice. Upon demyelination, we observed myelin repair deficits, neurotoxic microglia and astroglia, and increased axon degeneration. Experimental autoimmune encephalomyelitis activity progressed faster in mutant mice equally accompanied by activated glial cells. This study therefore provides direct evidence on HERV-W ENV's contribution to the overall negative impact of this activated viral entity in MS.
Brain and Mind Center University of Sydney NSW 2050 Sydney Australia
Department of Neurology Palacky University Olomouc 77146 Olomouc Czech Republic
Department of Neurology University of Bern CH 3010 Bern Switzerland
GeNeuro Innovation 69008 Lyon France
Neuroscience Center Zurich University of Zürich and ETH Zürich CH 8057 Zürich Switzerland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016213
- 003
- CZ-PrNML
- 005
- 20231026110157.0
- 007
- ta
- 008
- 231013s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1073/pnas.2308187120 $2 doi
- 035 __
- $a (PubMed)37695891
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Gruchot, Joel $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000348944679
- 245 10
- $a Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment / $c J. Gruchot, I. Lewen, M. Dietrich, L. Reiche, M. Sindi, C. Hecker, F. Herrero, B. Charvet, U. Weber-Stadlbauer, HP. Hartung, P. Albrecht, H. Perron, U. Meyer, P. Küry
- 520 9_
- $a The human endogenous retrovirus type W (HERV-W) has been identified and repeatedly confirmed as human-specific pathogenic entity affecting many cell types in multiple sclerosis (MS). Our recent contributions revealed the encoded envelope (ENV) protein to disturb myelin repair by interfering with oligodendroglial precursor differentiation and by polarizing microglial cells toward an axon-damage phenotype. Indirect proof of ENV's antiregenerative and degenerative activities has been gathered recently in clinical trials using a neutralizing anti-ENV therapeutic antibody. Yet direct proof of its mode of action can only be presented here based on transgenic ENV expression in mice. Upon demyelination, we observed myelin repair deficits, neurotoxic microglia and astroglia, and increased axon degeneration. Experimental autoimmune encephalomyelitis activity progressed faster in mutant mice equally accompanied by activated glial cells. This study therefore provides direct evidence on HERV-W ENV's contribution to the overall negative impact of this activated viral entity in MS.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 12
- $a endogenní retroviry $x genetika $7 D020077
- 650 _2
- $a neuroglie $7 D009457
- 650 _2
- $a geneticky modifikovaná zvířata $7 D030801
- 650 _2
- $a myelinová pochva $7 D009186
- 650 12
- $a roztroušená skleróza $x genetika $7 D009103
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lewen, Isabel $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000198186218
- 700 1_
- $a Dietrich, Michael $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000240556711
- 700 1_
- $a Reiche, Laura $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0000000223589925
- 700 1_
- $a Sindi, Mustafa $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/0009000828902336
- 700 1_
- $a Hecker, Christina $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany
- 700 1_
- $a Herrero, Felisa $u Institute of Veterinary Pharmacology and Toxicology, University of Zürich-Vetsuisse, CH-8057 Zürich, Switzerland $1 https://orcid.org/0000000220551147
- 700 1_
- $a Charvet, Benjamin $u GeNeuro Innovation, 69008 Lyon, France
- 700 1_
- $a Weber-Stadlbauer, Ulrike $u Institute of Veterinary Pharmacology and Toxicology, University of Zürich-Vetsuisse, CH-8057 Zürich, Switzerland $u Neuroscience Center Zurich, University of Zürich and ETH Zürich, CH-8057 Zürich, Switzerland $1 https://orcid.org/0000000252789993
- 700 1_
- $a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $u Brain and Mind Center, University of Sydney, NSW 2050 Sydney, Australia $u Department of Neurology, Palacky University Olomouc, 77146 Olomouc, Czech Republic $1 https://orcid.org/0000000206146989 $7 nlk20050167624
- 700 1_
- $a Albrecht, Philipp $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $1 https://orcid.org/000000017987658X
- 700 1_
- $a Perron, Hervé $u GeNeuro Innovation, 69008 Lyon, France $1 https://orcid.org/0000000225517685
- 700 1_
- $a Meyer, Urs $u Institute of Veterinary Pharmacology and Toxicology, University of Zürich-Vetsuisse, CH-8057 Zürich, Switzerland $u Neuroscience Center Zurich, University of Zürich and ETH Zürich, CH-8057 Zürich, Switzerland $1 https://orcid.org/0000000172440345
- 700 1_
- $a Küry, Patrick $u Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany $u Department of Neurology, University of Bern, CH-3010 Bern, Switzerland $1 https://orcid.org/0000000226541126
- 773 0_
- $w MED00010472 $t Proceedings of the National Academy of Sciences of the United States of America $x 1091-6490 $g Roč. 120, č. 38 (2023), s. e2308187120
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37695891 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026110151 $b ABA008
- 999 __
- $a ok $b bmc $g 1999999 $s 1202575
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 120 $c 38 $d e2308187120 $e 20230911 $i 1091-6490 $m Proceedings of the National Academy of Sciences of the United States of America $n Proc Natl Acad Sci U S A $x MED00010472
- LZP __
- $a Pubmed-20231013
